

## 2013 PHARMACEUTICALS RESEARCH REVIEW



PHM099D

Various Analysts  
***Project Analyst***

ISBN:

**bcc** | Research  
Market Forecasting

**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481  
866-285-7215, 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
**Custom Reports:**  
[carol.laverty@bccresearch.com](mailto:carol.laverty@bccresearch.com)

## TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 ABOUT BCC RESEARCH REVIEWS	2
FOREWORD	2
CHAPTER 2 ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (REPORT PHM119A)	4
INTRODUCTION	4
STUDY GOALS AND OBJECTIVES	4
REASONS FOR STUDY	4
SCOPE OF STUDY	4
METHODOLOGY AND INFORMATION SOURCES	5
ANALYST CREDENTIALS	5
RELATED BCC RESEARCH REPORTS	5
SUMMARY	5
<i>TABLE 1 TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	6
<i>FIGURE 1 TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, 2011-2017 (\$ MILLIONS)</i>	7
INDUSTRY OVERVIEW	8
THE CIRCULATORY SYSTEM	8
BLOOD VESSEL STRUCTURE	8
BLOOD FLOW	9
CONDITIONS	10
THROMBUS	10
EMBOLUS	11
ALTERATIONS IN VENOUS FLOW	12
DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM	12
<i>TABLE 2 FACTORS PREDISPOSING TO PULMONARY EMBOLISM OF VIRCHOW'S TRIAD</i>	13
HEMOSTASIS (THE CLOTTING PROCESS)	14
DISEASES ASSOCIATED WITH THROMBOEMBOLISM	15
ACUTE CORONARY SYNDROME	15
Ischemic Heart Disease	16
Etiology	16
Mechanisms of Coronary Atherosclerosis	16
Pathophysiology of Ischemia	17
ANGINA PECTORIS	18
ACUTE ISCHEMIA AND MYOCARDIAL INFARCTION	19
CHRONIC ISCHEMIC CARDIOMYOPATHY	19
SUDDEN CARDIAC DEATH	19
ATRIAL FIBRILLATION	20
Causes	20
CEREBROVASCULAR DISEASE	21
Peripheral Artery Disease (PAD)	22
Prevalence and Incidence	22
Symptoms	22
Causes	23

<b>TOPIC</b>	<b>PAGE NO.</b>
STENTS AND THROMBOSIS	23
DEMOGRAPHICS	24
<i>TABLE 3 TOTAL GLOBAL POPULATION BY SELECTED GEOGRAPHICAL REGION, 2000 TO 2050</i>	25
<i>FIGURE 2 TOTAL GLOBAL POPULATION BY SELECTED GEOGRAPHICAL REGION, 2000 TO 2050 (MILLIONS)</i>	25
CARDIOVASCULAR, VTE, ATRIAL FIBRILLATION AND STROKE DEMOGRAPHICS	26
Venous Thromboembolism	26
Cardiovascular Disease	27
<i>TABLE 4 HEART DISEASE DEATHS BY COUNTRY</i>	28
Stroke	28
<i>TABLE 5 U.S. STROKE DEMOGRAPHICS BY SELECTED CHARACTERISTICS, 2010 (THOUSANDS)</i>	29
Atrial Fibrillation	30
VENOUS THROMBOEMBOLISM AND LIFESTYLE	30
VENOUS THROMBOEMBOLISM AND AIR TRAVEL	31
CHAPTER 3 GLOBAL MARKETS FOR DRUG-DEVICE COMBINATIONS (REPORT PHM045C)	34
INTRODUCTION	34
STUDY GOALS AND OBJECTIVES	34
THE IMPORTANCE OF THIS STUDY	34
INTENDED AUDIENCE	35
SCOPE AND FORMAT	35
METHODOLOGY AND INFORMATION SOURCES	36
ANALYST CREDENTIALS	36
RELATED BCC RESEARCH REPORTS	36
SUMMARY	37
SCOPE OF THE INDUSTRY	37
DRUG-DEVICE COMBINATIONS: THE GLOBAL MARKET	37
<i>TABLE 6 SALES OF DRUG DEVICE COMBINATION PRODUCTS, THROUGH 2017 (\$ BILLIONS)</i>	38
<i>FIGURE 3 SALES OF DRUG DEVICE COMBINATION PRODUCTS, 2011-2017 (\$ BILLIONS)</i>	38
TECHNOLOGY AND PATENT ACTIVITY	39
THE CENTRAL ROLE OF THE FDA	39
CURRENT STATUS OF THE DRUG DEVICE COMBINATION INDUSTRY	40
ROLE OF THE FDA	40
<i>TABLE 7 EXAMPLES OF FDA APPROVED COMBINATION PRODUCTS</i>	42
OFFICE OF COMBINATION PRODUCTS ORGANIZATIONAL STRUCTURE	42
HIGHLY ADVANCED TECHNOLOGIES ARE A MARKET CORE	43
EXAMPLES OF THE MOST PATH-BREAKING PRODUCTS	43
FDA CLASSIFICATION SCHEME FOR INDIVIDUAL SEGMENTS	44
<i>TABLE 8 FDA CLASSIFICATION SCHEME FOR COMBINATION PRODUCTS</i>	45
THE RELATION BETWEEN NANOTECHNOLOGY AND COMBINATION PRODUCTS	45
<i>TABLE 9 COMPANIES INVOLVED IN DRUG RELATED NANOTECHNOLOGY R&amp;D OR MANUFACTURING</i>	46
FDA TRENDS IN REVIEWING COMBINATION PRODUCTS	48

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 10 FDA TRENDS IN COMBINATION PRODUCT APPLICATIONS, 2003-2010 (NO. OF PRODUCT SUBMISSIONS)</i>	48
<i>TABLE 11 FDA COMBINATION PRODUCT CATEGORIES IN FY2010</i>	49
CHAPTER 4 GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES (REPORT PHM005C)	52
INTRODUCTION	52
REASONS FOR DOING THE STUDY	52
SCOPE OF REPORT	52
METHODOLOGY/INFORMATION SOURCES	52
INTENDED AUDIENCE	53
ANALYST CREDENTIALS	53
RELATED BCC RESEARCH REPORTS	53
SUMMARY	53
<i>TABLE 12 GLOBAL MARKET FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES, THROUGH 2017 (\$ MILLIONS)</i>	54
<i>FIGURE 4 GLOBAL MARKET FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES, 2011 AND 2017 (%)</i>	54
INDUSTRY OVERVIEW	56
EPIDEMIOLOGY AND ETIOLOGY OF SEXUALLY TRANSMITTED DISEASES	56
TRENDS IN GLOBAL TRANSMISSION OF STDs	56
DIAGNOSIS OF STD	56
VISUAL OBSERVATION	56
BLOOD/TISSUE STAINING	57
AUTOMATED TESTING	57
<i>TABLE 13 MAJOR MANUFACTURERS OF AUTOMATED STD TESTS, 2012</i>	57
NONAUTOMATED STD DIAGNOSTIC TESTING	57
<i>TABLE 14 MAJOR MANUFACTURERS OF RAPID AND LABORATORY DIAGNOSTIC STD KITS, 2012</i>	58
VACCINES	58
<i>TABLE 15 MAJOR MANUFACTURERS OF VACCINES FOR STDs</i>	59
MARKET ANALYSIS BY DISEASE	59
HPV/GENITAL WARTS	59
Diagnostic Product Market	59
<i>TABLE 16 HPV DIAGNOSTIC PRODUCTS, MANUFACTURER AND MARKET SHARE, 2011 (%)</i>	59
GONORRHEA	60
Diagnostic Product Market	60
<i>TABLE 17 GONORRHEA DIAGNOSTIC PRODUCT MANUFACTURERS AND PRODUCT NAMES</i>	60
Treatment Market	60
<i>TABLE 18 MAJOR GONORRHEA TREATMENT MANUFACTURERS AND PRODUCTS</i>	61
HEPATITIS A, B AND C	61
Diagnostic Product Market	61
<i>TABLE 19 HEPATITIS A, B AND C DIAGNOSTIC PRODUCT MARKET SHARE AND REVENUES BY TYPE OF TEST, 2011 (\$ MILLIONS/%)</i>	61
Treatment Market	61
<i>TABLE 20 MARKET STANDING OF MAJOR HEPATITIS B AND C TREATMENT MANUFACTURERS BY REVENUES, 2011 (\$ MILLIONS)</i>	62

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 5 TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET AND THEIR MARKET SHARE, 2011 (%)</i>	62
HIV/AIDS	63
Diagnostic Market	63
<i>TABLE 21 HIV DIAGNOSTIC PRODUCT MARKET SHARE AND REVENUES BY TYPE, 2011 (\$ MILLIONS/%)</i>	63
Treatment Market	63
<i>TABLE 22 HIV/AIDS TREATMENT MANUFACTURER MARKET STANDING BY REVENUES, 2011 (\$ MILLIONS/%)</i>	64
<i>FIGURE 6 MARKET SHARE OF LEADING COMPANIES IN THE HIV/AIDS TREATMENT MARKET, 2011 (%)</i>	64
MARKET SHARE, BY DISEASE	65
<i>TABLE 23 NUMBER OF DIAGNOSTIC AND PHARMACEUTICAL MANUFACTURERS, BY DISEASE TREATED, WITH REVENUES AND MARKET SHARE, 2011 (\$ MILLIONS/%)</i>	65
MERGERS AND ACQUISITIONS	65
<i>TABLE 24 SELECTED MERGERS AND ACQUISITIONS, 2008-2012 (\$ MILLIONS)</i>	66
CHAPTER 5 HISTONE METHYLTRANSFERASES: GLOBAL MARKETS FOR RESEARCH TOOLS, DIAGNOSTICS AND DRUG DISCOVERY (REPORT PHM128A)	68
INTRODUCTION	68
STUDY GOALS AND OBJECTIVES	68
REASONS FOR DOING THIS STUDY	68
SCOPE AND FORMAT	69
METHODOLOGY AND INFORMATION SOURCES	69
INTENDED AUDIENCE	69
ANALYST CREDENTIALS	70
RELATED BCC RESEARCH REPORTS	70
SUMMARY	70
<i>TABLE 25 GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, THROUGH 2018 (\$ MILLIONS)</i>	72
<i>FIGURE 7 GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, 2011-2018 (\$ MILLIONS)</i>	72
INTRODUCTION TO HISTONE METHYLTRANSFERASES RESEARCH AND PRODUCT DEVELOPMENT	73
DNA METHYLATION	75
DNA METHYLTRANSFERASES	76
DNA METHYLATION DETECTION TECHNIQUES	77
HISTONE MODIFICATIONS	78
<i>TABLE 26 DIFFERENT CLASSES OF MODIFICATIONS IDENTIFIED ON HISTONES</i>	78
<i>TABLE 27 MAIN CATEGORIES IN HISTONE-MODIFICATION ENZYMES</i>	79
CHROMATIN METHYLATION REACTION	80
<i>FIGURE 8 SCHEMATIC PRESENTATION OF METHYLATION REACTION</i>	80
HISTONE METHYLTRANSFERASES: LYSINE METHYLATION	81
<i>TABLE 28 EXAMPLES OF HISTONE LYSINE METHYLATION AND ITS FUNCTIONAL OUTCOMES</i>	82
Role of Lysine Methylation in Chromatin Transcription	83
HISTONE METHYLTRANSFERASES: ARGININE METHYLATION	83
<i>TABLE 29 EXAMPLES OF HISTONE ARGININE METHYLATION AND ITS FUNCTIONAL OUTCOMES</i>	85
Role of Arginine Methylation in Chromatin Transcription	85

<b>TOPIC</b>	<b>PAGE NO.</b>
PRDM FAMILY AND HISTONE METHYLTRANSFERASE ACTIVITY	86
<i>TABLE 30 PRDM FAMILY MEMBERS, THEIR RELATED ENZYMATIC ACTIVITY AND BINDING PARTNERS</i>	87
<i>TABLE 31 EXAMPLES OF EPIGENETIC ALTERATIONS IN DIFFERENT PATHOLOGIES</i>	88
CHAPTER 6 UBIQUITIN PROTEASOME: GLOBAL MARKETS FOR RESEARCH TOOLS, DIAGNOSTICS AND DRUG DISCOVERY (REPORT PHM066B)	90
INTRODUCTION	90
STUDY GOALS AND OBJECTIVES	90
REASONS FOR DOING THIS STUDY	90
SCOPE AND FORMAT	91
METHODOLOGY AND INFORMATION SOURCES	91
INTENDED AUDIENCE	91
ANALYST CREDENTIALS	91
RELATED BCC RESEARCH REPORTS	92
SUMMARY	92
<i>TABLE 32 GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND DEVELOPMENT, THROUGH 2018 (\$ MILLIONS)</i>	93
<i>FIGURE 9 GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND DEVELOPMENT, 2010-2018 (\$ MILLIONS)</i>	93
OVERVIEW OF SCIENTIFIC BACKGROUND AND SIGNIFICANCE OF UBIQUITIN PROTEASOME RESEARCH	94
UBIQUITIN PROTEASOME SYSTEM: ITS MAJOR COMPONENTS AND ENZYMATIC PROCESS	94
<i>FIGURE 10 SCHEMATIC REPRESENTATION OF ENZYMATIC STEPS IN UBIQUITINATION REACTION</i>	95
<i>FIGURE 11 HIERARCHICAL STRUCTURE OF UBIQUITIN PROTEASOME SYSTEM</i>	95
<i>TABLE 33 ENZYMATIC COMPONENTS OF UBIQUITINATION/ DEUBIQUITINATION REACTION</i>	96
Chain Topology and its Significance in Cellular Function	96
PROTEASOME MACHINERY	97
20S Core Particle	97
19S Core Particle	98
Protein Degradation Process	98
Proteasome as a Target for Drug Discovery	99
UBIQUITIN DOMAIN PROTEINS AND UBIQUITIN-LIKE MODIFIERS	101
<i>TABLE 34 UBIQUITIN LIKE MODIFIERS (UBLs), THEIR FUNCTION AND ASSOCIATED SUBSTRATES</i>	101

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 1 TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, THROUGH 2017 (\$ MILLIONS)	6
TABLE 2 FACTORS PREDISPOSING TO PULMONARY EMBOLISM OF VIRCHOW'S TRIAD	13
TABLE 3 TOTAL GLOBAL POPULATION BY SELECTED GEOGRAPHICAL REGION, 2000 TO 2050	25
TABLE 4 HEART DISEASE DEATHS BY COUNTRY	28
TABLE 5 U.S. STROKE DEMOGRAPHICS BY SELECTED CHARACTERISTICS, 2010 (THOUSANDS)	29
TABLE 6 SALES OF DRUG DEVICE COMBINATION PRODUCTS, THROUGH 2017 (\$ BILLIONS)	38
TABLE 7 EXAMPLES OF FDA APPROVED COMBINATION PRODUCTS	42
TABLE 8 FDA CLASSIFICATION SCHEME FOR COMBINATION PRODUCTS	45
TABLE 9 COMPANIES INVOLVED IN DRUG RELATED NANOTECHNOLOGY R&D OR MANUFACTURING	46
TABLE 10 FDA TRENDS IN COMBINATION PRODUCT APPLICATIONS, 2003-2010 (NO. OF PRODUCT SUBMISSIONS)	48
TABLE 11 FDA COMBINATION PRODUCT CATEGORIES IN FY2010	49
TABLE 12 GLOBAL MARKET FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES, THROUGH 2017 (\$ MILLIONS)	54
TABLE 13 MAJOR MANUFACTURERS OF AUTOMATED STD TESTS, 2012	57
TABLE 14 MAJOR MANUFACTURERS OF RAPID AND LABORATORY DIAGNOSTIC STD KITS, 2012	58
TABLE 15 MAJOR MANUFACTURERS OF VACCINES FOR STDs	59
TABLE 16 HPV DIAGNOSTIC PRODUCTS, MANUFACTURER AND MARKET SHARE, 2011 (%)	59
TABLE 17 GONORRHEA DIAGNOSTIC PRODUCT MANUFACTURERS AND PRODUCT NAMES	60
TABLE 18 MAJOR GONORRHEA TREATMENT MANUFACTURERS AND PRODUCTS	61
TABLE 19 HEPATITIS A, B AND C DIAGNOSTIC PRODUCT MARKET SHARE AND REVENUES BY TYPE OF TEST, 2011 (\$ MILLIONS/%)	61
TABLE 20 MARKET STANDING OF MAJOR HEPATITIS B AND C TREATMENT MANUFACTURERS BY REVENUES, 2011 (\$ MILLIONS)	62
TABLE 21 HIV DIAGNOSTIC PRODUCT MARKET SHARE AND REVENUES BY TYPE, 2011 (\$ MILLIONS/%)	63
TABLE 22 HIV/AIDS TREATMENT MANUFACTURER MARKET STANDING BY REVENUES, 2011 (\$ MILLIONS/%)	64
TABLE 23 NUMBER OF DIAGNOSTIC AND PHARMACEUTICAL MANUFACTURERS, BY DISEASE TREATED, WITH REVENUES AND MARKET SHARE, 2011 (\$ MILLIONS/%)	65
TABLE 24 SELECTED MERGERS AND ACQUISITIONS, 2008-2012 (\$ MILLIONS)	66
TABLE 25 GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, THROUGH 2018 (\$ MILLIONS)	72
TABLE 26 DIFFERENT CLASSES OF MODIFICATIONS IDENTIFIED ON HISTONES	78
TABLE 27 MAIN CATEGORIES IN HISTONE-MODIFICATION ENZYMES	79
TABLE 28 EXAMPLES OF HISTONE LYSINE METHYLATION AND ITS FUNCTIONAL OUTCOMES	82
TABLE 29 EXAMPLES OF HISTONE ARGININE METHYLATION AND ITS FUNCTIONAL OUTCOMES	85
TABLE 30 PRDM FAMILY MEMBERS, THEIR RELATED ENZYMATIC ACTIVITY AND BINDING PARTNERS	87
TABLE 31 EXAMPLES OF EPIGENETIC ALTERATIONS IN DIFFERENT PATHOLOGIES	88

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 32 GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND DEVELOPMENT, THROUGH 2018 (\$ MILLIONS)	93
TABLE 33 ENZYMATIC COMPONENTS OF UBIQUITINATION/ DEUBIQUITINATION REACTION	96
TABLE 34 UBIQUITIN LIKE MODIFIERS (UBLs), THEIR FUNCTION AND ASSOCIATED SUBSTRATES	101



**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 1 TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, 2011-2017 (\$ MILLIONS)	7
FIGURE 2 TOTAL GLOBAL POPULATION BY SELECTED GEOGRAPHICAL REGION, 2000 TO 2050 (MILLIONS)	25
FIGURE 3 SALES OF DRUG DEVICE COMBINATION PRODUCTS, 2011-2017 (\$ BILLIONS)	38
FIGURE 4 GLOBAL MARKET FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES, 2011 AND 2017 (%)	54
FIGURE 5 TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET AND THEIR MARKET SHARE, 2011 (%)	62
FIGURE 6 MARKET SHARE OF LEADING COMPANIES IN THE HIV/AIDS TREATMENT MARKET, 2011 (%)	64
FIGURE 7 GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, 2011-2018 (\$ MILLIONS)	72
FIGURE 8 SCHEMATIC PRESENTATION OF METHYLATION REACTION	80
FIGURE 9 GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND DEVELOPMENT, 2010-2018 (\$ MILLIONS)	93
FIGURE 10 SCHEMATIC REPRESENTATION OF ENZYMATIC STEPS IN UBIQUITINATION REACTION	95
FIGURE 11 HIERARCHICAL STRUCTURE OF UBIQUITIN PROTEASOME SYSTEM	95